Integer Holdings Corporation's stock surged by 8.08% today, reaching a 20-day high, as the Nasdaq-100 rose by 1.90% and the S&P 500 gained 1.27%.
This increase comes amid significant legal challenges for the company, as it faces a class action lawsuit for allegedly misleading investors about its competitive position in the electrophysiology market. The lawsuit claims that Integer overstated its growth potential while concealing declining sales of key products, which could lead to substantial financial losses for shareholders. Investors are encouraged to join the lawsuit to protect their rights, with a registration deadline set for February 9, 2026.
The implications of these allegations are profound, as they may undermine investor confidence and affect the company's long-term growth prospects. The stock's recent performance, despite these challenges, suggests that some investors may be optimistic about the company's ability to navigate these legal hurdles.
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 93.38 USD with a low forecast of 75.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 93.38 USD with a low forecast of 75.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 86.470
Low
75.00
Averages
93.38
High
140.00
Current: 86.470
Low
75.00
Averages
93.38
High
140.00
Truist
Richard Newitter
Buy
maintain
$86 -> $95
2025-12-18
Reason
Truist
Richard Newitter
Price Target
$86 -> $95
AI Analysis
2025-12-18
maintain
Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on Integer to $95 from $86 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.
Raymond James
Outperform
maintain
2025-12-18
Reason
Raymond James
Price Target
2025-12-18
maintain
Outperform
Reason
Raymond James notes that Wednesday evening, the Wall Street Journal reported that Irenic Capital Management has taken a sub-3% position and activist approach to Integer, including a private letter to the board earlier this week. The report states an intent to push for a board refresh and potential sale under the belief that public markets undervalue the company. The firm's conversations confirm these central tenets. Raymond agrees that the current valuation underappreciates Integer's assets. The firm ultimately thinks the stock can perform as a public equity as the current drags abate. However, a sale would likely draw interest at valuations above current trading levels and could offer a more immediate path to upside, it argues. Regardless of a transaction, Raymond sees room for equity holders to be rewarded over time. The firm has an Outperform rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ITGR
Unlock Now
Citi
Neutral
maintain
$69 -> $75
2025-12-11
Reason
Citi
Price Target
$69 -> $75
2025-12-11
maintain
Neutral
Reason
Citi raised the firm's price target on Integer to $75 from $69 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.
Truist
Buy
downgrade
$88 -> $86
2025-11-24
Reason
Truist
Price Target
$88 -> $86
2025-11-24
downgrade
Buy
Reason
Truist lowered the firm's price target on Integer to $86 from $88 and keeps a Buy rating on the shares. Following the firm's meeting with the company CEO, Truist continues to believe that it could take a few quarters before investors underwrite a re-acceleration in the second half of FY26, the analyst tells investors in a research note.
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
